Monte Rosa Therapeutics (GLUE) Insider Manning Buys $42K of Stock

Anthony Manning, a notable figure, recently acquired 10,000 shares of Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE) on June 29, 2026. The shares were purchased at an average price of $4.16, amounting to a total transaction value of $41,600. This insider buying activity was not part of a pre-planned trading program.

Insider Buying and Selling at Monte Rosa Therapeutics, Inc.

In addition to Anthony Manning's purchase, there were other notable transactions at Monte Rosa on the same date. Filip Janku, the Chief Medical Officer, was involved in multiple transactions, including a planned sale of 6,000 shares at $22.95 and an unplanned purchase of 6,000 shares at $7.56.

Other Institutional Activity in Monte Rosa Therapeutics

Several institutional investors have also been active in Monte Rosa Therapeutics. Price T Rowe Associates Inc /MD/ increased its holdings by 1,601,284 shares, bringing its total to 6,720,188 shares valued at approximately $110.5 million, marking a 31.3% increase. Versant Venture Management, LLC, added 1,978,873 shares, ending with 6,361,560 shares worth around $104.6 million, a 45.2% increase. BlackRock, Inc. also grew its position by 1,456,523 shares, totaling 5,637,684 shares valued at $92.7 million, reflecting a 34.8% increase.

Monte Rosa Therapeutics, Inc. Stock Up 99.5%

On Wednesday, shares of Monte Rosa Therapeutics traded near $24.20. The company has a market capitalization of about $2.04 billion. It is currently not profitable, with a forward P/E ratio of -13.34. The stock has seen a 52-week low of $4.12 and a high of $25.77. Its 50-day moving average is $19.09, while the 200-day moving average stands at $16.34. Monte Rosa maintains a strong liquidity position with a current ratio of 9.54 and a quick ratio of 9.44.

Analysts Set New Price Targets

Analysts are optimistic about Monte Rosa Therapeutics' prospects. On June 30, 2026, Guggenheim maintained its 'buy' rating with a price target of $35.00. Earlier, JP Morgan also maintained a 'buy' rating with a target of $31.00 on May 11, 2026. Overall, the consensus among six analysts is a 'buy' rating, with a target mean price of $32.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing small molecule precision medicines that leverage the body's natural processes to selectively degrade harmful proteins. The company is working on several programs, including treatments for MYC-driven tumors, autoimmune diseases, and various cancers. Founded in 2019, Monte Rosa employs 187 people and is led by CEO Dr. Markus Warmuth.

Bottom Line

Anthony Manning's recent purchase of Monte Rosa Therapeutics shares highlights ongoing interest in the company's potential. While the stock has experienced significant price fluctuations, analysts remain optimistic with strong buy ratings and a favorable target price. Investors often watch insider transactions like these for potential insights into a company's prospects.